BioTheranostics Overview

  • Founded
  • 1996
  • Status
  • Acquired/​Merged
  • Employees
  • 108
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 3

BioTheranostics General Information


Developer of commercial-stage molecular diagnostics system designed to offer predictive tests for cancer treatment. The company's system is focused on early-stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID), respectively and provides diagnostic, prognostic and predictive tests, enabling doctors to address unmet medical needs and to make difficult decisions about extended endocrine therapy for ER+ breast cancer patients.

Contact Information

Formerly Known As
SDL Acquisition, AviaraDX
Ownership Status
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Diagnostic Equipment
Laboratory Services (Healthcare)
Other Healthcare Services
Parent Company
Primary Office
  • 9640 Towne Centre Drive
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (877) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioTheranostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Debt - PPP 27-Apr-2020 000.00 Completed
4. Later Stage VC 12-Apr-2019 00.000 000.00 Completed Generating Revenue
3. Later Stage VC 21-Jan-2016 0000 0000 0000 Completed Generating Revenue
2. Merger/Acquisition 11-Sep-2008 $60M $8M 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 19-Nov-2007 $8M $8M 0000 Completed Generating Revenue
To view BioTheranostics’s complete valuation and funding history, request access »

BioTheranostics Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000,000 00.000000 000 00.00 00.00 00 00.00 00.000
To view BioTheranostics’s complete cap table history, request access »

BioTheranostics Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of commercial-stage molecular diagnostics system designed to offer predictive tests for cancer treatment. The
San Diego, CA
108 As of 2016
000000000 - 000.00


r in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint oc
0000000000 000000000
Cambridge, MA
000 As of 0000
00 0000-00-00


psum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolo
0000000000 000000000
Boulder, CO
000 As of 0000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioTheranostics Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Foundation Medicine Corporate Backed or Acquired Cambridge, MA 000 00000 00000000000
00000000 Venture Capital-Backed Boulder, CO 000 00000 00000000 00000
00000000 000000000 Venture Capital-Backed Wuxi, China 00000 00000000000 00000
000000 00000000 Venture Capital-Backed Vancouver, Canada 0 000.00 00000000000 000.00
00000000 000000 Formerly VC-backed Redwood City, CA 000 00000 00000000 00000
You’re viewing 5 of 31 competitors. Get the full list »

BioTheranostics Executive Team (15)

Name Title Board Seat Contact Info
Donald Hardison Chief Executive Officer, President & Board Member
Gail Sloan Chief Financial Officer
William Zondler Chief Information Officer
Andy Lavagnino Contract Controller
Matt Sargent Vice President & Chief Commercial Officer
You’re viewing 5 of 15 executive team members. Get the full list »

BioTheranostics Board Members (9)

Name Representing Role Since
Adam Lessler MD Evidity Health Capital Board Observer 000 0000
Alejandro Sanchez Evidity Health Capital Board Member 000 0000
David Kabakoff Ph.D HealthQuest Capital Board Member 000 0000
Donald Hardison BioTheranostics Chief Executive Officer, President & Board Member 000 0000
Eric Bednarski Ph.D MVM Partners Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

BioTheranostics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioTheranostics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ABS Capital Partners Growth/Expansion Minority 000 0000 000000 0
SDL Ventures Venture Capital Minority 000 0000 000000 0
To view BioTheranostics’s complete investors history, request access »